Literature DB >> 29375650

Molecular Adsorbent Recirculating System as a Diagnostic and Therapeutic Modality.

S B Hicks1, J H Tabibian2,3.   

Abstract

Despite the many advancements in liver transplantation (LT), mortality in patients with hepatic failure remains high, and to date, many patients die while awaiting LT. The molecular adsorbent recirculating system (MARS®) is an extracorporeal liver support system intended to provide short-term metabolic detoxification, often as a vital bridge to LT. We report the case of a 41-year-old non-Hispanic White male who developed worsening multi-factorial encephalopathy in the setting of decompensated alcoholic cirrhosis. He continued to deteriorate despite supportive medical therapy, and extensive investigation for alternative causes of encephalopathy aside from hepatic was unrevealing; as a result, there was concern that his encephalopathy was due to irreversible causes from which he may not recover appropriately following LT. We herein: i) describe the implementation of MARS as a diagnostic intervention for encephalopathy of uncertain etiology in a patient with end stage liver disease who, on the basis of prompt psychomotor improvement, underwent LT 19 days post-MARS implementation with an excellent clinical outcome and thus ii) propose the use of extracorporeal liver support not only as a short-term bridge but also as a diagnostic (and potentially therapeutic) measure in cases of cryptogenic encephalopathy, particularly in the setting of advanced liver disease.

Entities:  

Keywords:  Bioartificial liver; Cirrhosis; Hemofiltration; Hepatic encephalopathy; Liver transplantation; Outcomes research; Prognosis

Year:  2017        PMID: 29375650      PMCID: PMC5784443          DOI: 10.4172/1747-0862.1000301

Source DB:  PubMed          Journal:  J Mol Genet Med        ISSN: 1747-0862


  7 in total

1.  Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support.

Authors:  J Stange; S R Mitzner; T Risler; C M Erley; W Lauchart; H Goehl; S Klammt; P Peszynski; J Freytag; H Hickstein; M Löhr; S Liebe; W Schareck; U T Hopt; R Schmidt
Journal:  Artif Organs       Date:  1999-04       Impact factor: 3.094

2.  Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome.

Authors:  Li-Min Guo; Jing-Yuan Liu; Dao-Zhen Xu; Bao-Shun Li; Hao Han; Ling-Hang Wang; Wei-Yan Zhang; Lian-He Lu; Xia Guo; Feng-Xia Sun; Hong-Yu Zhang; Xiao-Dong Liu; Jian-Ping Zhang; Yun Yao; Zhong-Ping He; Min-Min Wang
Journal:  Liver Int       Date:  2003       Impact factor: 5.828

Review 3.  Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis.

Authors:  Ming Luo; Jian-Yang Guo; Wu-Kui Cao
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 4.  Emerging indications for albumin dialysis.

Authors:  Sambit Sen; Roger Williams; Rajiv Jalan
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

5.   Albumin dialysis with MARS for the treatment of anabolic steroid-induced cholestasis.

Authors:  Francia C Díaz; Esteban Sáez-González; Salvador Benlloch; Diego Álvarez-Sotomayor; Isabel Conde; Begoña Polo; María García; María Rodríguez; Martín Prieto
Journal:  Ann Hepatol       Date:  2016 Nov-Dec 2016       Impact factor: 2.400

Review 6.  Management of hepatic encephalopathy in the hospital.

Authors:  Michael D Leise; John J Poterucha; Patrick S Kamath; W Ray Kim
Journal:  Mayo Clin Proc       Date:  2014-01-08       Impact factor: 7.616

7.  Reduction of elevated cytokine levels in acute/acute-on-chronic liver failure using super-large pore albumin dialysis treatment: an in vitro study.

Authors:  Adrian Dominik; Jan Stange; Claudia Pfensig; Luise Borufka; Helga Weiss-Reining; Martin Eggert
Journal:  Ther Apher Dial       Date:  2013-11-12       Impact factor: 1.762

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.